Inclusion Criteria:

- Case has an original pathology report showing, epithelial ovarian, peritoneal, or
fallopian tube carcinoma.

- Cases must meet one of the following classifications: Recurrent: Complete Response
following primary therapy and a period of absence of no measurable disease;
Persistent: Partial Response following 6 cycles of a platinum based therapy with
measurable disease remaining or Refractory: Stable Disease or Progressive Disease
during primary platinum therapy.

- Case must have a commercial ChemoFx drug response marker final report

Exclusion Criteria:

- Cases with evidence of synchronous primary endometrial cancer or a past history of
primary endometrial cancer are excluded unless all of the following conditions are
met: Stage not greater than I-B; Less than 3 mm invasion without vascular or
lymphatic invasion; No poorly differentiated subtype, including papillary serous,
clear cell, or other FIGO Grade 3 lesion.